“Those who saw no opportunity in generic small molecules have been, I think, proven wrong by the recent successes in some of these generic launches,” Gedeon Richter believes, as it championed the recent launch in European markets of its generic version of Bayer’s anticoagulant powerhouse Xarelto (rivaroxaban).
“Rivaroxaban is one of the examples of products going off-patent that provide opportunity for the generics players in Europe